Healthcare -
Biotechnology - NASDAQ - US
$ 56.65
-3.31 %
$ 3.11 B
Market Cap
-28.32
P/E
CASH FLOW STATEMENT
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Arcellx, Inc.
| Net Income | -107 M |
| Depreciation & Amortization | -10.3 M |
| Capital Expenditures | -13.4 M |
| Stock-Based Compensation | 61.1 M |
| Change in Working Capital | -30.8 M |
| Others | -26.9 M |
| Free Cash Flow | -96.9 M |
Cash Flow
Millions
| Dec-2024 | Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | |
|---|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||||
| Net Income | (107.3) | (70.7) | (188.7) | (65.0) | (32.1) | (18.0) | (8.3) |
| Depreciation & Amortization | (10.3) | 2.0 | 1.3 | 1.0 | 0.6 | 0.3 | 93 K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | (3.6) | 100 K | 0 |
| Stock Based Compensation | 61.1 | 41.8 | 21.5 | 6.8 | 1.1 | 0.1 | 66 K |
| Other Operating Activities | 3.8 | 9.0 | 62.1 | 0.2 | 3.6 | 100 K | 0.9 |
| Change in Working Capital | (30.8) | 225.4 | 4.5 | 2.7 | 1.8 | (1.3) | 0.4 |
| Cash From Operations | (83.5) | 207.6 | (99.3) | (54.2) | (28.7) | (18.8) | (6.9) |
| INVESTING CASH FLOW | |||||||
| Capital Expenditures | (13.4) | (21.4) | (2.3) | (5.8) | (0.9) | (3.8) | (0.5) |
| Other Items | (169.6) | (133.1) | (115.4) | (74.2) | 0 | 0 | 0 |
| Cash From Investing Activities | (183.0) | (154.5) | (117.7) | (80.0) | (0.9) | (3.8) | (0.5) |
| FINANCING CASH FLOW | |||||||
| Common Stock Repurchased | 1.2 | 0 | 0 | 24 K | 0 | 0 | 0 |
| Total Debt Repaid | (39.8) | (29.4) | (9.7) | (0.4) | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 15.8 | 8.8 | 2.5 | 118.9 | 41.7 | 42.7 | 12.5 |
| Cash From Financing Activities | (24.1) | 279.2 | 252.6 | 118.5 | 41.7 | 42.7 | 12.5 |
| CHANGE IN CASH | |||||||
| Net Change In Cash | (290.6) | 332.2 | 35.6 | (15.8) | 12.1 | 20.0 | 5.1 |
| FREE CASH FLOW | |||||||
| Free Cash Flow | (96.9) | 186.1 | (101.6) | (60.0) | (29.6) | (22.6) | (7.3) |